Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE S&P Capital IQ
NEW YORK, Sept. 6, 2013 /PRNewswire/ -- S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Epigenomics AG.
Epigenomics AG (OTC: EPGNY; FSE: ECX) is a molecular diagnostics company focusing on developing and commercializing of in vitro diagnostic (IVD) tests for the screening and diagnosis of cancer. The company's products are based on a technology platform, which relies on a fundamental biological phenomenon called DNA methylation as a source for the discovery of highly informative and disease-specific biomarkers which are at the core of every diagnostic test it has developed so far.
Epigenomics develops and commercializes diagnostic tests in colorectal cancer (CRC) and in lung cancer; both via direct marketing and sales efforts of IVD kits and through non-exclusive licensing partnerships for the biomarkers constituting the basis for these products. The company directly addresses certain market segments with its own products, while others are or will be served by partners through the licenses granted to them.
The company's lead product is Epi proColon®, a blood-based test for the early detection of CRC which relies on its DNA methylation biomarker, Septin9. The majority of Epigenomics' activities are focused on the introduction of Epi proColon® as an IVD kit in the United States, the world's largest commercial market for molecular diagnostic products. In 2012, the company completed the Premarket Approval (PMA) application and is expecting an approval decision from the U.S. Food and Drug Administration (FDA) before the end of 2013. Blood-based tests using the Septin9 biomarker are available worldwide through the company's partners, including Abbott Molecular Diagnostics, Inc., Quest Diagnostics, Inc., ARUP Laboratories, Inc., Gamma Dynacare, and Companion Dx Reference Lab. The product and diagnostic service offerings are performed on the basis of licenses granted to these partners by Epigenomics.
In July 2013, Epigenomics announced findings from a health economic study done at Stanford University School of Medicine. According to the study, Septin9 testing provided potential for saving lives while being health economically beneficial as an attractive screening alternative to established methods for a population that would otherwise be non-compliant to CRC screening.
On March 7, 2013, Epigenomics announced that it signed a licensing agreement with BioChain for Septin9 in China.
Standard & Poor's Factual Stock Report coverage on Epigenomics AG will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit http://www.epigenomics.com/de for additional information.
About Standard & Poor's Factual Stock Reports
Currently profiling approximately 500 issuers, Standard & Poor's Factual Stock Reports, produced by S&P Capital IQ, increase market awareness of issuers in the investment community with insightful commentary and key statistics and information. Standard & Poor's Factual Stock Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information about covered companies to reach a wide investor audience of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is underwritten by the issuer, S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.
Standard & Poor's Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations. S&P Capital IQ does not trade on its own account.
About S&P Capital IQ
S&P Capital IQ, a part of McGraw Hill Financial, is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. Evaluated pricing is prepared by Standard & Poor's Securities Evaluations, Inc., a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit: www.spcapitaliq.com.
Antje Zeise (Manager Investor Relations)
S&P Capital IQ
Richard Albanese, 212-438-3647
Michael Privitera, 212-438-6679
©2012 PR Newswire. All Rights Reserved.